EXELIXIS, INC. (EXEL) Stock
1 member of Congress disclosed 3 trades in EXEL since 2019: 2 purchases and 1 sale, most recently Donna Shalala (sale, Jun 4, 2019). 8 of the hedge funds AlphaScala tracks reported EXEL in 13F filings for the quarter ended Sep 30, 2026; the largest reported position is Renaissance Technologies's at $730.62M. Company insiders reported 0 open-market buys and 1 sale on SEC Form 4 in the 90 days to Nov 2, 2026.
Which members of Congress traded EXELIXIS, INC. (EXEL)?
Most recent: Donna Shalala (sale, Jun 4, 2019); records start Jan 9, 2019.
| Politician | Trade date | Type | Amount |
|---|---|---|---|
| Donna Shalala D-FL · House | 2019-06-04 | sale | $1k – $15k |
| Donna Shalala D-FL · House | 2019-02-06 | purchase | $1k – $15k |
| Donna Shalala D-FL · House | 2019-01-09 | purchase | $1k – $15k |
From STOCK Act periodic transaction reports. House filings as of Nov 1, 2026.
See all EXEL political trades →Which hedge funds own EXEL?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Renaissance Technologies Jim Simons (founder) | 13.43M | $730.62M | -2% |
| D.E. Shaw David Shaw | 5.55M | $302.07M | +54% |
| Millennium Management Israel Englander | 1.22M | $66.31M | +30% |
| Marshall Wace | 832K | $45.24M | +177% |
| Bridgewater Associates Ray Dalio | 401K | $21.81M | -17% |
| Citadel Ken Griffin | 71K | $3.86M | -91% |
| Hussman Investment Trust John Hussman | 42K | $2.45M | n/a |
| Blackstone | 13K | $692.9K | -33% |
13F holdings as of Sep 30, 2026
Explore all tracked funds →Are EXELIXIS, INC. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Aug 10, 26 | Beckerle Mary C | Director | SELL | 9.8K | $527K |
SEC Form 4 filings as of Nov 2, 2026
See cluster-buy signals across all tickers →EXEL price chart
Powered by TradingViewWhat does EXELIXIS, INC. do?
Exelixis Inc. is an oncology-focused biotechnology company dedicated to the discovery, development, and commercialization of new medicines for difficult-to-treat cancers. Its lead product, CABOMETYX tablets (cabozantinib), treats advanced renal cell carcinoma in patients following prior anti-angiogenic therapy and supports expansion into indications like neuroendocrine tumors. COMETRIQ capsules (cabozantinib) address progressive, metastatic medullary thyroid cancer. The company also markets COTELLIC (cobimetinib) and advances a pipeline including zanzalintinib, evaluated in trials such as STELLAR-303 for metastatic colorectal cancer in combination with immune checkpoint inhibitors. Exelixis leverages expertise in chemistry, biology, and strategic partnerships to develop small molecules, bispecific antibodies, antibody-drug conjugates, and other innovative anti-cancer therapies. These efforts target tyrosine kinases like MET, AXL, RET, and VEGF receptors, aiming to inhibit cancer growth and metastasis. Founded in 1994 and headquartered in Alameda, California, Exelixis plays a vital role in oncology by challenging treatment norms and broadening therapeutic options for patients worldwide.